GlassScriptPhysician profile
Robert L Venuti
NPI 1548274442
$13,735.32
in general payments reported to CMS, 2019-2025
44 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,792 · 2020: $1,746 · 2021: $1,073 · 2022: $2,276 · 2023: $2,818 · 2024: $1,397 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,807 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,806.77 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,372.62 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,645.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,566.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,543.16 | 2019-2023 | |
| Amgen INC. | $1,463.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $793.94 | 2021-2025 | |
| Lilly USA, LLC | $508.37 | 2019-2025 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $327.67 | 2019-2025 | Rexulti |
| Glaxosmithkline, LLC. | $319.59 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $308.07 | 2019-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $224.87 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $220.09 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $210.46 | 2022-2025 | Auvelity |
| Medtronic Vascular, INC. | $202.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.22 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Venuti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.